Analysis of Prognostic Factors in Metastatic Tumors of the Pancreas

Masetti, Michele; Zanini, Nicola; Martuzzi, Federica; Fabbri, Carlo; Mastrangelo, Laura; Landolfo, Giovanni; Fornelli, Adele; Burzi, M; Vezzelli, Elena; Jovine, Elio

doi:10.1097/mpa.0b013e3181bae9b3

Cited by 73 publications

(77 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 1-year survival rates for such patients from the AJCC melanoma staging database is 41%. Perhaps even more controversial is the resection of multiple organ-site disease [9][10][11].…”

Section: Discussionmentioning

confidence: 99%

“…Wong et al [10] retrospectively analyzed 47 patients who underwent thoracotomy for lung metastases from malignant melanoma. They demonstrated that, in selected patients, thoracotomy with complete excision of the metastatic deposits results in improved survival and should be considered the treatment of choice (the overall 5-year survival rate was 25% with a median survival of 19 months).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pancreatic Resection for Metastatic Melanoma. Case Report and Review of the Literature

Sperti

Polizzi

Beltrame

et al. 2010

J Gastrointest Canc

View full text Add to dashboard Cite

show abstract

“…The 1-year survival rates for such patients from the AJCC melanoma staging database is 41%. Perhaps even more controversial is the resection of multiple organ-site disease [9][10][11].…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Pancreatic Resection for Metastatic Melanoma. Case Report and Review of the Literature

Sperti

Polizzi

Beltrame

et al. 2010

J Gastrointest Canc

View full text Add to dashboard Cite

show abstract

“…In some cases, despite these radiological features, it can be difficult to distinguish a pancreatic RCC metastasis from a primary pancreatic ductal and lesions should be evaluated with biopsy [22, 23]. There are several factors affecting survival of patients with metastases of RCC: the site and number of foci, the performance status and the disease free interval of the patients [24, 25]. Pancreatic metastasectomy of RCC was reported to improve survival in selected patients [4–7].…”

Section: Discussionmentioning

confidence: 99%

Metachronous pancreatic metastases from renal cell carcinoma: is there a place of Active-Surveillance before deferred deliberately Molecular Target Agent?

et al. 2016

View full text Add to dashboard Cite

BackgroundMetastatic renal cell cancer is a heterogeneous disease due to its diverse morphological features, the prognostic categories based on clinical criteria. Sometimes indolent course without any significant symptoms can be differentiated before the introduction of novel targeted agents. This observation led to interest in a strategy of deferring systemic therapy in the era of effective systemic therapies.Case presentationWe report of a 78-year-old Moroccan man with pancreatic metastasis from renal cell carcinoma which occurred 14 years from right nephrectomy. Indolent disease based on body computed tomography imaging with 4 years follow-up was recognized. Active surveillance with deferred antiangiogenic multikinase inhibitor at disease progression was proposed. Nowadays, the patient is under oncological follow-up, he is in a good state of health, and he is disease-free for 48 months from the diagnosis of the tumor and for 20 months from the start of the treatment with SunitinibConclusionsActive surveillance before target therapy may be a suitable approach to ensure long progression-free survival with minimal side-effects and better quality of life in asymptomatic, low-volume, metastatic disease. Further prospective studies with biomarker validation are required to define the patients most likely to benefit from this approach.

show abstract

“…2 Masetti et al analyzed the prognostic factors relating to metastatic tumors in the pancreas and found two and five-year survival rates of 57.1% and 34.3% in cases of pancreatic metastasis due to breast cancer, respectively. 28 Surgical resection in cases with disease limited to the pancreas is considered to be the main form of treatment, despite its morbidity.…”

Section: Discussionmentioning

confidence: 99%

Solitary pancreatic metastasis from breast cancer: case report and review of literature

et al. 2019

View full text Add to dashboard Cite

CONTEXT: Pancreatic metastases from primary malignant tumors at other sites are rare, constituting about 2% of the neoplasms that affect the pancreas. Pancreatic metastasis from breast cancer is extremely rare and difficult to diagnose, because its clinical and radiological presentation is similar to that of a primary pancreatic tumor. CASE REPORT: A 64-year-old female developed a lesion in the pancreatic tail 24 months after neoadjuvant therapy, surgery and adjuvant radiation therapy for right-side breast cancer (ductal carcinoma). She underwent distal pancreatectomy with splenectomy and left adrenalectomy, and presented an uneventful outcome. The immunohistochemical analysis on the surgical specimen suggested that the lesion originated from the breast. CONCLUSION: In cases of pancreatic lesions detected in patients with a previous history of breast neoplasm, the possibility of pancreatic metastasis should be carefully considered.

show abstract

Analysis of Prognostic Factors in Metastatic Tumors of the Pancreas

Abstract: There may be a subset of patients with pancreatic metastases who are able to benefit from surgery with respect to improved long-term survival. Symptoms at diagnosis, presentation with primary tumor, surgical resection, and pathologic diagnosis seem to be important prognostic factors.

Cited by 73 publications

References 41 publications

Pancreatic Resection for Metastatic Melanoma. Case Report and Review of the Literature

Pancreatic Resection for Metastatic Melanoma. Case Report and Review of the Literature

Metachronous pancreatic metastases from renal cell carcinoma: is there a place of Active-Surveillance before deferred deliberately Molecular Target Agent?

Solitary pancreatic metastasis from breast cancer: case report and review of literature

Contact Info

Product

Resources

About